Report adverse events:
Adverse events should be reported to the Vifor Pharma group.
Supporting you to support your patients with hyperkalaemia
Some of these provide more information for you and some are for you to pass onto your patients to help them understand hyperkalaemia and the medicine they have been prescribed and what else they can do to help lower their K+ levels.
Please click on the appropriate tab above to access the relevant resources.
Information on the relevance and impact of the 3 key electrolytes sodium, magnesium and calcium in the context of patients treated with Veltassa®.
A reminder of the key facts and figures around the prevalence of hyperkalaemia and how important it is to control serum K+ levels to enable patients with chronic kidney disease and/or heart failure to stay on guideline-recommended therapy.
Concise summaries of AMETHYST-DN, OPAL-HK, PEARL-HF and AMBER, providing details on study design, patient population, efficacy and safety endpoints.
A more in-depth look at how Veltassa® works.
A visual guide on how to take Veltassa® and a helpful chart to note when the dose was taken so that other medicines are not taken within the precautionary 3-hour period.
A simple means to help you share key information about hyperkalaemia with your patients. It includes a description of hyperkalaemia, who is at risk, symptoms and treatments, and tips for a low-potassium diet. A chart is also provided that may help patients learn about low- and high-potassium foods.
A brochure to help you educate your patients on the correct diet choices for a low-potassium lifestyle. The brochure outlines high- and low-potassium foods, as well as other tips for adhering to a low-potassium diet.
A brochure to help you educate patients on the possible severe consequences of hyperkalaemia. The brochure provides essential information for patients about hyperkalaemia, including its causes, symptoms, treatment options, and the role of diet.
K+, potassium; MoA, mechanism of action.
If you, as an HCP, wish to receive electronic promotional and non-promotional information from the Vifor Pharma Group, please subscribe using this form.